Breakthrough T1D Funded Clinical Trial Testing Islet Cell Transplantation with Eledon's Tegoprubart Expands to Include People with Type 1 Diabetes and Kidney Disease
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- A new clinical trial funded by Breakthrough T1D recently launched and is testing islet cell transplantation paired with Eledon Pharmaceuticals' investigational immunosuppression therapy tegoprubart in people living with type 1 diabetes (T1D) and...
Covered in this story
Call it yourself
No calls on $ELDN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Eledon Pharmaceuticals Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.